Global Ceftazidime Injection Market Research Report 2022

Ceftazidime injection is a western medicine preparation, mainly used for respiratory tract infections and urinary tract infections caused by sensitive bacteria.Since the global outbreak of COVID-19, these drugs have also entered a stage of shortage .
Due to the COVID-19 pandemic, the global Ceftazidime Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Ceftazidime Injection market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Ceftazidime Injection landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
1g/vial accounting for % of the Ceftazidime Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Ceftazidime Injection include Teligent, Pfizer, B Braun, Sagent, WG Critical Care, GSK, Allergan, CSPC Zhongnuo Pharmaceutical and Anhui Welman, etc. In terms of revenue, the global 3 largest players have a % market share of Ceftazidime Injection in 2021.
This report focuses on Ceftazidime Injection volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Ceftazidime Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Ceftazidime Injection Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
1g/vial
2g/vial
6g/vial
Segment by Application
Hospital
Clinics
Recovery Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Teligent
Pfizer
B Braun
Sagent
WG Critical Care
GSK
Allergan
CSPC Zhongnuo Pharmaceutical
Anhui Welman
Guangzhou Baiyunshan Tianxin Pharmaceutical
Hainan Hailing Chemipharma